<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Halperin, Jonathan L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Oral Anticoagulants</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">30-32</style></pages><abstract><style  face="normal" font="default" size="100%">This article discussed some of the novel targets for anticoagulants, the two most immediate of which are Factor Xa and Factor IIa (thrombin), as well as overview of the characteristics of five new anticoagulant agents and current studies that involve these agents.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>